New CF drug safety check: will VTD be safer for those who struggled with previous treatment?
NCT ID NCT06683092
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study follows 200 people with cystic fibrosis (ages 6 and up) who had mental health or liver issues while taking the drug elexacaftor/tezacaftor/ivacaftor (ETI) and had to stop or change it. They will now start a newer triple therapy called vanzacaftor/tezacaftor/deutivacaftor (VTD). Researchers will track side effects through daily diaries, surveys, and liver tests for up to a year to see if VTD is better tolerated.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- vanzacaftor/tezacaftor/deutivacaftor (VTD)
- What this could lead to
- If successful, this study could help doctors understand how to safely use VTD in people with CF who have had mental health or liver problems from other treatments.
- What could go wrong
- This is an observational study, not a treatment trial. It will not test if VTD works, only monitor side effects. Results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CYSTIC FIBROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Boston Children's Hospital
RECRUITINGBoston, Massachusetts, 02215, United States
-
Children's Hospital Colorado
RECRUITINGAurora, Colorado, 80045, United States
-
Emory University
RECRUITINGAtlanta, Georgia, 30322, United States
-
Indiana University
RECRUITINGBloomington, Indiana, 47405, United States
-
Johns Hopkins University
RECRUITINGBaltimore, Maryland, 21287, United States
-
Kansas University Medical Center
RECRUITINGKansas City, Kansas, 66160, United States
-
Massachusetts General Hospital
NOT_YET_RECRUITINGBoston, Massachusetts, 02114, United States
-
National Jewish Health
RECRUITINGDenver, Colorado, 80206, United States
-
Nemours Children's
RECRUITINGWilmington, Delaware, 19803, United States
-
Nemours Children's
RECRUITINGJacksonville, Florida, 32207, United States
-
Nemours Children's
RECRUITINGOrlando, Florida, 32827, United States
-
Nemours Children's
RECRUITINGPensacola, Florida, 32514, United States
-
Seattle Children's Hospital
RECRUITINGSeattle, Washington, 98105, United States
-
University of Alabama at Birmingham
RECRUITINGBirmingham, Alabama, 35233, United States
-
University of Michigan
RECRUITINGAnn Arbor, Michigan, 48109, United States
-
University of Pittsburgh Medical Center
RECRUITINGPittsburgh, Pennsylvania, 15224, United States
-
University of Texas Southwestern Medical Center
RECRUITINGDallas, Texas, 75235, United States
-
Washington University at St. Louis
NOT_YET_RECRUITINGSt Louis, Missouri, 63130, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A smartphone tool may help cystic fibrosis patients survive the lung transplant waitlist
- Can a smartphone app reveal how CF treatments really work at home?
- Can a peer coach help young people take control of their chronic illness?
- Could a single antibiotic be enough for cystic fibrosis lung infections?
- Early use of powerful CF drugs may boost growth in young children
- Hands-On therapy may soothe cystic fibrosis pain without drugs